文献速递肝病消化道肿瘤与早癌

连接去分化与β-catenin功能障碍的基因调控网络在肝细胞癌中的动态变化及预测药物反应

Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2019-04-04

研究利用癌症基因组图谱、LIRI-JP项目及自有转录组、转染和小鼠转基因实验数据,识别出将LIN28B依赖的去分化与β-catenin(CTNNB1)功能障碍功能连接的基因调控网络,并用人类细胞系和体内表达数据构建并验证了定量数学模型,该模型可通过网络工具评估肝细胞癌样本的网络状态并预测治疗药物对网络的影响。

要点

  • LIN28B与CTNNB1同SMARCA4、Let-7b(MIRLET7B)、SOX9、TP53和MYC形成基因调控网络。
  • 该网络功能见于肝细胞癌和胃肠道肿瘤,网络状态与肝细胞癌预后负相关。
  • 数学模型可预测网络组分表达变化及药物对网络的影响,已开发网络工具供评估。

核心结论

  • 识别并建模该基因调控网络为理解肝细胞癌预后及促瘤基因影响肝细胞癌发展的机制提供了见解。

研究设计与样本

  • 利用癌症基因组图谱、LIRI-JP(肝癌-理化学研究所,日本项目)数据及本研究的转录组、转染和小鼠转基因实验,识别基因调控网络,并用人类细胞系和体内表达数据生成和验证定量数学模型。

主要发现

  • LIN28B和CTNNB1与SMARCA4、Let-7b(MIRLET7B)、SOX9、TP53和MYC形成基因调控网络。
  • 该网络功能在肝细胞癌和胃肠道肿瘤中检出,但在其他癌症类型中未检出。
  • 网络状态与肝细胞癌预后负相关,与过度增殖、去分化和HGF/MET通路激活正相关,提示其促成增殖类肝细胞癌典型的转录组谱。
  • 数学模型预测当网络组分的表达变化或被药物抑制时其他网络组分表达的变化。
  • 网络组分表达的动态揭示出正常条件下可逆切换、而在肝细胞癌中不可逆切换的不同细胞状态。

关键数值与推荐

  • 数学模型可通过网络工具获取,该工具能评估肝细胞癌样本的网络状态并预测治疗药物对网络的影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Alterations of individual genes variably affect the development of hepatocellular carcinoma (HCC). Thus, we aimed to characterize the function of tumor-promoting genes in the context of gene regulatory networks (GRNs). METHODS: Using data from The Cancer Genome Atlas, from the LIRI-JP (Liver Cancer - RIKEN, JP project), and from our transcriptomic, transfection and mouse transgenic experiments, we identify a GRN which functionally links LIN28B-dependent dedifferentiation with dysfunction of β-catenin (CTNNB1). We further generated and validated a quantitative mathematical model of the GRN using human cell lines and in vivo expression data. RESULTS: We found that LIN28B and CTNNB1 form a GRN with SMARCA4, Let-7b (MIRLET7B), SOX9, TP53 and MYC. GRN functionality is detected in HCC and gastrointestinal cancers, but not in other cancer types. GRN status negatively correlates with HCC prognosis, and positively correlates with hyperproliferation, dedifferentiation and HGF/MET pathway activation, suggesting that it contributes to a transcriptomic profile typical of the proliferative class of HCC. The mathematical model predicts how the expression of GRN components changes when the expression of another GRN member varies or is inhibited by a pharmacological drug. The dynamics of GRN component expression reveal distinct cell states that can switch reversibly in normal conditions, and irreversibly in HCC. The mathematical model is available via a web-based tool which can evaluate the GRN status of HCC samples and predict the impact of therapeutic agents on the GRN. CONCLUSIONS: We conclude that identification and modelling of the GRN provide insights into the prognosis of HCC and the mechanisms by which tumor-promoting genes impact on HCC development. LAY SUMMARY: Hepatocellular carcinoma (HCC) is a heterogeneous disease driven by the concomitant deregulation of several genes functionally organized as networks. Here, we identified a gene regulatory network involved in a subset of HCCs. This subset is characterized by increased proliferation and poor prognosis. We developed a mathematical model which uncovers the dynamics of the network and allows us to predict the impact of a therapeutic agent, not only on its specific target but on all the genes belonging to the network.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Gérard C, Di-Luoffo M, Gonay L, et al. Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma. J Hepatol. 2019. PMID: 30953666. doi:10.1016/j.jhep.2019.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。